Clinical : Improved A1C for Patients, Plus Reduction in Frequency of Hypoglycemia
The d‑Nav® Program and technology has been studied extensively. Peer-reviewed research evaluating the d‑Nav® Program showed that patients safely improve A1C with a lower frequency of both mild and severe hypoglycemia.
Insulin users experience rapid improvement and sustainability of A1C values: nearly 90% of patients improve their A1C within 3 months. Nearly 97% achieve A1C <9% and the long term average A1C for patients who use the d‑Nav® Program stay within the target range.
The d‑Nav® technology accounts for both the high and low sugars. Therefore, it has been shown to drastically reduce the frequency and severity of hypoglycemia. The average frequency of mild hypoglycemia for d‑Nav® Program users is approximately 6 events per patient per year, and frequency of severe hypoglycemia is roughly 2.5 for every 100 patient-years.
Source: 1. Rates and predictors of hypoglycemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study., Diabetes Obes Metab. 2016 Sep;18(9):907-15. doi: 10.1111/dom.12689
2. Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005-2011., Diabetes Care. 2016 Mar;39(3):363-70. doi: 10.2337/dc15-0858
Financial : Better Care at a Lower Rx Cost
Patients with advanced type 2 diabetes often take several different drugs to lower their glucose. In addition, such patients are heavy consumers of healthcare with an average total cost of care exceeding $25,000 per patient per year.
According to the Standards of Medical Care in Diabetes, if A1C is above goal, treatment should be intensified by adding additional agents. In the US, the average A1C for insulin users is > 8.5% and therefore most patients are treated with additional agents, some of which cost hundreds of dollars per month.
Schneider and colleagues evaluated cost reductions associated with the d-Nav® Program and showed a potential reduction of costs totaling thousands of dollars per patient per year. This 9-month study which assessed the impact of the d-Nav® Program on costs showed:
- Large reduction in anti-diabetes Rx
- Reduced cost of insulin
- Reduced utilization due to health improvement
Patients with long-standing type 2 diabetes are usually frustrated with their disease and with the care they are receiving. The d-Nav® Program offers a no-judgment zone, encouraging patients to simply take a different dose of insulin. A satisfaction survey conducted by Schneider and colleagues showed that within 3 months, patient’s satisfaction with their care improved from a 2.2 to a 3.7 on a 4.0 scale.
The d-Nav® Program has been well studied and select peer-reviewed research is listed below. Please call us at 734-743-2838 to learn more.
Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial, Lancet. 2019 Mar 16;393(10176):1138-1148.
Temporary Reductions in Insulin Requirements Are Associated with Hypoglycemia in Type 2 Diabetes, Diabetes Technology & Therapeutics, Vol. 20, No. 12.
Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® story, Clinical Diabetes and Endocrinology volume 4, Article number: 8 (2018).
Impact of a Novel Insulin Management Service on Non-insulin Pharmaceutical Expenses, Journal of Health Economics and Outcomes Research, Vol. 6, Issue 1, 2018.
Cost-effectiveness analysis of d-Nav® for people with diabetes at risk of foot ulcers, Diabetes Ther. 2016 Sep; 7(3): 511–525.
Can a tool that automates insulin titration be a key to diabetes management?, Diabetes Technol Ther. 2012 Aug;14(8):675-82.
- Are glucose readings sufficient to adjust insulin dosage?, Diabetes Technol Ther. 2011 Jan;13(1):85-92.